世界の医療・医薬品産業レポート

TOP  >  疾患別治験・パイプラインレポート  >  呼吸器  >  咳 - パイプラインレビュー 2017年下半期

咳 - パイプラインレビュー 2017年下半期
Cough - Pipeline Review, H2 2017

レポートタイトル 咳 - パイプラインレビュー 2017年下半期
出版社名 Global Markets Direct
発刊日 2017-08-29
体裁 PDF / 83 ページ
シングルユーザ価格 US$ 2,000
レポート分類 疾患別治験・パイプラインレポート
地域 グローバル
領域 呼吸器
疾患名
薬剤名 -
企業名 -
備考 ※ ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※ 本レポートは、英文です。PDF(電子媒体)での納品となります。

レポート概要

このレポートは、世界の主要国における上記疾患の治療薬開発についての包括的情報、さまざまな開発ステージでの比較分析、薬剤ターゲット、作用機序(MoA)、投与方法(RoA)、分子タイプ別の薬剤評価、および最新情報、ニュースやプレスリリースなどを提供します。
また、上記疾患における治療薬開発に関わる主要企業概要、開発後期および中止プロジェクトの特集などを提供します。


Global Market Direct社のレポートは、20の治療領域および3000もの適応症をカバーした治験薬を特集しています。
本レポートは、Global Market Direct社独自のデータベース、企業/大学ウェブサイト、SEC書類、企業や大学のウェブサイトからのプレゼンテーションやプレスリリース、および業界特有の第三者情報源、自社分析を基にしたデータや情報を盛り込んでいます。


本レポートは、意思決定能力を高め、競争上の優位性を得るための効果的な戦略を立案するのに役立ちます。
ファーストインクラスやベストインクラス製品を作り出すため、新たなターゲットやMOAを特定することにより、R&Dパイプラインを強化します。


注)本レポートの一部のセクションは、該当疾患におけるデータの可用性や妥当性に基づいて、削除または変更される場合があります。

目次

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cough - Overview
Cough - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Cough - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cough - Companies Involved in Therapeutics Development
Alitair Pharmaceuticals Inc
AstraZeneca Plc
BELLUS Health Inc
Charleston Laboratories Inc
Conrig Pharma ApS
Daewoong Pharmaceutical Co Ltd
Develco Pharma Schweiz AG
Grunenthal GmbH
Hyundai Pharmaceutical Co Ltd
Merck & Co Inc
Orbis Biosciences Inc
Patara Pharma Inc
PhytoHealth Corp
Pila Pharma AB
SolAeroMed Inc
Vernalis Plc
Cough - Drug Profiles
AX-8 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
benzonatate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLU-5937 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCP-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCP-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCP-07 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCP-08 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLX-121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
codeine + guaifenesin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cromolyn sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DWJ-1340 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gefapixant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
guaifenesin + hydrocodone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
guaifenesin ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hydrocodone bitartrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lesogaberan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
levodropropizine CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDR-16523 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ORB-110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
orvepitant maleate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pemirolast potassium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PHCA-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-1226 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
serlopitant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-015 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XEND-0501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cough - Dormant Projects
Cough - Discontinued Products
Cough - Product Development Milestones
Featured News & Press Releases
May 22, 2017: Merck Announces Presentation of Phase 2 Results for MK-7264, an Investigational, P2X3 Receptor Antagonist, Being Evaluated for the Treatment of Chronic Cough
Apr 27, 2017: BELLUS Health to present at Bloom Burton & Co. Healthcare Investor Conference
Apr 24, 2017: BELLUS Health Announces Grant of New U.S. Patent Covering Lead Compound for Chronic Cough
Sep 07, 2016: Patara Pharma Announces Positive Phase 2 Results for the Treatment of Refractory Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis
May 16, 2016: Afferent Pharmaceuticals Presents Updated Positive Results with AF-219 from Phase 2B Chronic Cough Study at the 2016 American Thoracic Society International Conference
May 03, 2016: Patara Pharma Appoints Biotechnology Industry Leader John Schmid to Board of Directors
Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Chronic Cough Clinical Data at the Upcoming American Thoracic Society 2016 International Conference
Sep 28, 2015: Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial
Jul 01, 2015: Spriaso Announces Approval of New Drug Application for the Long Acting Codeine Antitussive With a Popular Anti-Histamine
Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet
Sep 09, 2014: Charleston Laboratories Announces Key Clinical Updates for Novel Drug
Dec 11, 2013: Ario Pharma to Develop Novel Therapeutics for Respiratory Indications
Oct 10, 2013: Spriaso completes FDA Meeting on Tuxarin ER
Sep 09, 2013: Afferent Pharmaceuticals Reports Positive Phase 2 Clinical Data for the Company’s Lead P2X3 Antagonist, AF-219
Jan 06, 2012: Tris Pharma Announces US Patent Grant Covering Platform Technology
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Figures
Number of Products under Development for Cough, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

List of Tables
Number of Products under Development for Cough, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Cough - Pipeline by Alitair Pharmaceuticals Inc, H2 2017
Cough - Pipeline by AstraZeneca Plc, H2 2017
Cough - Pipeline by BELLUS Health Inc, H2 2017
Cough - Pipeline by Charleston Laboratories Inc, H2 2017
Cough - Pipeline by Conrig Pharma ApS, H2 2017
Cough - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017
Cough - Pipeline by Develco Pharma Schweiz AG, H2 2017
Cough - Pipeline by Grunenthal GmbH, H2 2017
Cough - Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2017
Cough - Pipeline by Merck & Co Inc, H2 2017
Cough - Pipeline by Orbis Biosciences Inc, H2 2017
Cough - Pipeline by Patara Pharma Inc, H2 2017
Cough - Pipeline by PhytoHealth Corp, H2 2017
Cough - Pipeline by Pila Pharma AB, H2 2017
Cough - Pipeline by SolAeroMed Inc, H2 2017
Cough - Pipeline by Vernalis Plc, H2 2017
Cough - Dormant Projects, H2 2017
Cough - Dormant Projects, H2 2017 (Contd..1), H2 2017
Cough - Discontinued Products, H2 2017
Loading....